Routine vaccination

• Infant Toddler: 2-dose series at age 9 months; 12 months

• Adolescents: 1-dose at age 18 years

Catch-up vaccination

• MenACWY-D:
  - Age 9-23 months: 2-dose series (dose 2 at least 12 weeks after dose 1; dose 2 may be administered as early as 8 weeks after dose 1 in travelers)
  - Age 2 years or older: 1 dose

• MenACWY-CRM:
  - Age 7-23 months: 2 doses, with a minimum interval of 2 months. The second dose is to be administered during the second year of life
  - Age 2 years or older: 1 dose

• MenACWY-TT:
  Age from 6 months of age: 1-dose followed by a booster dose at 12 months of age with an interval of at least 2 months after the last dose.

Note: An additional primary dose (before 12 months booster dose) may be considered appropriate for some individuals*.
* If an infant aged 6 months to less than 12 months of age is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and Y, consideration may be given to administering a second primary dose after an interval of 2 months from the first dose.

Special situations

Anatomic or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab):

• MenACWY-CRM:
  -Dose 1 at age 2 months: 4-dose series (additional 3 doses at age 4, 6, and 12 months)
  -Dose 1 at age 3–6 months: 3- or 4-dose series (dose 2 [and dose 3 if applicable] at least 8 weeks after previous dose until a dose is received at age 7 months or older, followed by an additional dose at least 12 weeks later and after age 12 months)
  -Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 12 weeks after dose 1 and after age 12 months)
  -Dose 1 at age 24 months or older: 2-dose series at least 8 weeks apart

• MenACWY-D:
  

• Persistent complement component deficiency or complement inhibitor use:
  - Age 9–23 months: 2-dose series at least 12 weeks apart
  - Age 24 months or older: 2-dose series at least 8 weeks apart

• Anatomic or functional asplenia, sickle cell disease, or HIV infection:
  - Age 9–23 months: Not recommended
  - Age 24 months or older: 2-dose series at least 8 weeks apart:
  - MenACWY-D must be administered at least 4 weeks after completion of PCV series.